Short Interest in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Rises By 119.5%

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 391,100 shares, a growth of 119.5% from the December 15th total of 178,188 shares. Approximately 2.0% of the shares of the company are short sold. Based on an average trading volume of 597,371 shares, the days-to-cover ratio is presently 0.7 days. Based on an average trading volume of 597,371 shares, the days-to-cover ratio is presently 0.7 days. Approximately 2.0% of the shares of the company are short sold.

Analysts Set New Price Targets

ARTV has been the topic of several research reports. Needham & Company LLC restated a “buy” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a report on Friday, October 17th. Wedbush boosted their price target on Artiva Biotherapeutics from $18.00 to $23.00 and gave the company an “outperform” rating in a research note on Friday, October 17th. HC Wainwright upped their price target on Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Jefferies Financial Group raised Artiva Biotherapeutics to a “strong-buy” rating in a report on Tuesday, November 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Institutional Investors Weigh In On Artiva Biotherapeutics

Hedge funds have recently made changes to their positions in the company. Bank of America Corp DE lifted its holdings in Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares during the last quarter. Prelude Capital Management LLC bought a new position in shares of Artiva Biotherapeutics in the third quarter valued at approximately $41,000. Ground Swell Capital LLC bought a new position in shares of Artiva Biotherapeutics in the second quarter valued at approximately $38,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $48,000. Finally, Bridgeway Capital Management LLC bought a new stake in Artiva Biotherapeutics during the 2nd quarter worth approximately $53,000.

Artiva Biotherapeutics Trading Down 6.7%

NASDAQ ARTV opened at $4.46 on Friday. Artiva Biotherapeutics has a 1-year low of $1.47 and a 1-year high of $7.46. The company has a market capitalization of $109.49 million, a price-to-earnings ratio of -1.73 and a beta of 2.92. The stock’s 50 day moving average is $3.96 and its two-hundred day moving average is $3.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its earnings results on Wednesday, November 12th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.04. On average, analysts predict that Artiva Biotherapeutics will post -4.95 earnings per share for the current year.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.